Outcomes of serial sessions of Activa mask combined with intense pulsed light therapy in patients with Meibomian gland dysfunction

Luca Vigo1, Marco Pellegrini2,3,4, Francesco Carones1, Vincenzo Scorcia5 and Giuseppe Giannaccare5*

Abstract

Background: To evaluate the effects on ocular surface signs and symptoms of serial sessions of heating and vibrating eye mask followed by intense pulsed light (IPL) therapy for the treatment of dry eye disease owing to meibomian gland dysfunction (MGD).

Methods: Consecutive patients with MGD whose signs and symptoms were not satisfactorily controlled with conventional therapy were included. Patients received 3 treatments performed at day 1, 15, and 45 incorporating a session with a newly-developed eye mask (Activa, SBS Sistemi, Turin, Italy) immediately followed by IPL therapy (E > Eye device, E-Swin, Paris, France). Patients were examined before the first session (T0) and 30 days after the last session (T1) for the measurement of: noninvasive break-up time (NIBUT); lipid layer thickness (LLT); tear meniscus height (TMH); meibomian gland loss (MGL); tear osmolarity. Ocular discomfort symptoms were ascertained by ocular surface disease index (OSDI) questionnaire.

Results: Thirty patients were ultimately included in the study. At T1, all objective ocular surface parameters improved significantly, except for TMH: NIBUT and LLT increased from 6.4 ± 1.7 to 8.6 ± 1.7 s and from 57.7 ± 15.5 to 81.3 ± 12.0 μm (all P < 0.001), while MGL and tear osmolarity decreased from 21.1 ± 17.3 to 17.0 ± 14.1% and from 302.0 ± 8.5 to 295.7 ± 6.9 mOsm/L (respectively, P = 0.004 and P < 0.001). In parallel, OSDI score decreased significantly from 49.8 ± 13.5 to 29.8 ± 10.6 (P < 0.001). In the historical control group of patients who underwent only IPL, NIBUT, LLT, tear osmolarity and OSDI improved significantly but not MGL and TMH.

Conclusions: Serial sessions incorporating the application of an eye mask producing heating and vibration immediately followed by IPL therapy are able to improve all ocular surface parameters as well as ocular discomfort symptoms in MGD patients.

Keywords: Dry eye, Meibomian gland dysfunction, Active mask, Eye mask, Intense pulsed light, Ocular surface

Background

Meibomian glands are holocrine sebaceous glands located in the upper and lower eyelids that open on the lid margin where they secrete lipids (meibum) forming the outermost layer of the tear film [1]. The qualitative and quantitative composition of meibum is essential to prevent excessive evaporation of the tear film, and thus to maintain the homeostasis of the ocular surface [2]. In meibomian gland dysfunction (MGD), gland terminal obstruction, occurring due to ductal epithelium keratinization and alteration of the meibum lipids, results in hyposecretion with subsequent tear film instability and increased evaporation [3]. If the disease progresses,
acinar degeneration and atrophy may ultimately lead to loss of meibomian glands. MGD is an area of growing interest since it represents the most common cause of evaporative dry eye disease [4]. Treatment options range from medications such as tear substitutes, essential fatty acids and antibiotics to self-administered eyelid hygiene and warm compresses. In refractory cases, in-office mechanical procedures (meibomian gland expression and probing), heat therapies (e.g. LipiFlow) or light-based treatment (intense pulsed light, IPL) can be employed alone or as complementary therapies to better cope with the disease [5–8].

The goal of MGD treatment is to improve the flow of meibomian gland secretions by liquefying materials that otherwise cause obstruction and by stimulating the function of meibomian glands. Theoretically, this goal could be reached by combining two different procedures in the same session: an eye mask producing heating and vibration could liquefy and release the meibum [9], while IPL could improve the function of meibomian glands through different mechanisms, including ablation of blood vessels, fluidification of meibum, Demodex eradication and reduction of inflammatory cytokines, among others [10–23].

The purpose of the present study was to evaluate the effects on objective parameters of the ocular surface and discomfort symptoms of serial combined treatments incorporating a session of heating and vibrating eye mask followed by IPL therapy.

Methods
Study and patients
This prospective pilot study included consecutive patients with MGD who attended for a routine visit the ocular surface office of the University Hospital of Catanzaro (Italy) between February 2021 and September 2021. The study followed the tenets of the Declaration of Helsinki for research involving human subjects. Written informed consent was obtained from all participants after the nature and possible consequences of the study had been explained to them. Patients aged 18–80 years were screened for eligibility according to the following inclusion criteria: presence of MGD defined as the presence of signs consistent with meibomian gland terminal duct obstruction with abnormal quantity and/or quality of meibomian gland secretions; presence of at least one ocular symptom related to MGD (dryness, foreign body sensation, irritation, and burning) not satisfactorily controlled by tear substitutes and eyelid hygiene; pathologi-cal value of Ocular Surface Disease Index (OSDI) score (≥ 13); and noninvasive break-up time (NIBUT) < 10 seconds (s) [9]. Patients were excluded from the study if one or more of the following conditions was present: active ocular inflammation; eyelid malposition; recent (within 3 months) ocular surgery; history of contact lens wearing; risk factors for retinal detachment (high myopia, lattice degeneration, and retinal break); and usage of anti-inflammatory eye drops (corticosteroid or cyclosporine) within 1 month [9].

Study treatment
All patients received 3 treatments performed at day 1, 15, and 45 incorporating a session with a newly-developed eye mask (Activa, SBS Sistemi, Turin, Italy) immediately followed by IPL therapy. Briefly, through a fully automated procedure (touch-screen controlled and user-friendly), the mask melts the meibum inside the glands and simultaneously squeezes them. The entire treatment is 15 minutes long, and consists of 2 phases in the following chronological order: 5 minutes of heating at 42°C (phase I); 10 minutes of combination of heating at 42°C and vibration up to 20Hz (phase II) [9]. IPL treatments were performed using E>Eye device (E-Swin, Paris, France), set on the proprietary “dry eye mode”, as previously described [24]. Treatment intensity was determined based on patient’s Fitzpatrick skin type, ranging from 9.8 to 13 J/cm^2 as per manufacturer recommendations [25]. During each treatment, protective eye shields were placed over the eyes and ultrasound gel was applied to the treatment area. Five flashes were applied for each eye starting from the inner canthus and ending on the temporal region below the lower eyelid, with slight overlapping applications.

Ocular surface workup
All patients were examined before the first session (T0) and 30 days after the last session (T1) by means of Idra (SBS Sistemi, Turin, Italy) for the automated measurement of the following parameters: NIBUT; lipid layer thickness (LLT); tear meniscus height (TMH); meibomian gland loss (MGL) of upper and lower eyelids [1]. Briefly, NIBUT was measured without the need for fluorescein dye after asking the patient to blink 3 consecutive times and then hold the eyes open. The measurement was repeated 3 times, and the mean value was recorded. LLT was estimated by observing the interference pattern and colours of the moving lipid tear film. TMH was measured along the lower lid margin immediately below the pupil. Infrared meibography was performed in the upper and lower eyelids and MGL was calculated by means of the image editing software ImageJ (National Institute of Health; http://imagej.nih.gov/ij) as the percentage of gland loss in relation to the total tarsal area of the lid. The I-Pen tear osmolarity system (I-Med Pharma Inc., Dollard des-Ormeaux, Quebec, Canada) was used to
measure tear osmolarity values. Ocular discomfort symptoms were ascertained by means of OSDI questionnaire.

During the study period, patients were advised to maintain unchanged their ongoing therapy based on tear substitutes instilled 4 times daily and eyelid hygiene before bedtime. Concomitant use of other therapeutic agents (for any ophthalmic disease) was prohibited throughout the study period.

Sample size
To determine the sample size of the study, an a priori sample size calculation was performed based on the data of the study of Yan et al. [26] In total, the enrollment of 11 patients was required to detect a mean change of 2.3 seconds in TBUT, with a power of 0.95 and a P value of 0.05.

Control group
Data from patients with MGD who have undergone IPL therapy alone at the same time intervals during the study period were retrospectively obtained in order to create an historical control group.

Statistical analysis
Statistical analysis was conducted using R (version 4.0.0) and RStudio (version 1.2.5042) software. Patients received treatments in both eyes and for statistical analysis data were derived from the eye with the lowest baseline NIBUT value (study eye). The normality of data distribution was assessed by means of the Kolmogorov-Smirnov test. Due to the non-normal distribution of data, the Wilcoxon test was performed to compare ocular surface parameters before and after treatment. A total of 72 patients with MGD were assessed for eligibility during the study period. Thirty of them (8 males, 22 females; mean age 49.1 ± 12.4 years) fulfilled the criteria and were included in the study. No patient was dropped from the study or used prohibited eye drops, so data from 30 patients were ultimately included in the analysis. Moreover, data from 34 patients (9 males, 25 females; mean age 56.2 ± 13.1 years) who underwent IPL as only therapy in the same period were retrospectively obtained and used as an historical control group. Demographic and clinical characteristics of patients belonging to both groups are reported in Table 1.

In patients undergoing Activa mask plus IPL therapy (study group), all objective ocular surface parameters except for TMH improved significantly at T1 compared to T0. In particular, mean values of NIBUT and LLT increased from 6.4 ± 1.7 to 8.6 ± 1.7 s and from 57.7 ± 15.5 to 81.3 ± 12.0 μm (all P < 0.001), while mean values of MGL and tear osmolarity decreased from 21.1 ± 17.3 to 17.0 ± 14.1% and from 302.0 ± 8.5 to 295.7 ± 6.9 mOsm/L (respectively, P = 0.004 and P < 0.001). In parallel, also ocular discomfort symptoms improved and mean OSDI score decreased significantly from 49.8 ± 13.5 at T0 to 29.8 ± 10.6 at T1 (P < 0.001). Conversely, mean values of TMH did not change significantly after treatment (P = 0.859).

In patients who underwent IPL therapy alone (historical control group), all objective ocular surface parameters except for TMH and MGL improved significantly at T1 compared to T0. In particular, mean values of NIBUT and LLT increased from 7.9 ± 2.9 to 11.4 ± 3.3 s and from 55.3 ± 11.2 to 76.2 ± 15.4 μm, while mean values of tear osmolarity decreased from 304.8 ± 11.1 to 302.0 ± 7.6 mOsm/L; in parallel, mean OSDI score significantly decreased from 44.8 ± 15.5 at T0 to 36.9 to 11.7 at T1 (always P < 0.001). Conversely, mean values of TMH and MGL did not change significantly (respectively, P = 0.510 and P = 0.637). Complete data concerning changes of ocular surface parameters before and after IPL with or without Activa mask are reported in Table 2.

Discussion
In the present study, we analyzed the effects on ocular surface in terms of objective signs and subjective symptoms of serial sessions of Activa mask combined with IPL therapy in patients with MGD not responding to conventional therapy. One month after the third session, all objective signs (NIBUT, LLT, MGL and tear osmolarity) improved significantly, except for TMH whose values were within the normal range already at baseline. In parallel, also ocular discomfort symptoms ameliorated significantly after these serial sessions. Further positive

### Table 1 Baseline characteristics of patients enrolled in the study

| Parameter               | IPL + Activa (study group) (n = 30) | IPL only (control group) (n = 34) |
|-------------------------|-------------------------------------|-----------------------------------|
| Age (years)             | 56.2 ± 13.1                         | 49.1 ± 12.4                       |
| Gender (M/F)            | 8/22                                | 9/25                              |
| Ethnicity               |                                     |                                   |
| European                | 27 (90%)                            | 30 (88%)                          |
| Other                   | 3 (10%)                             | 4 (12%)                           |
| Ocular rosacea          | 6 (20%)                             | 4 (12%)                           |
| Ocular allergy          | 3 (10%)                             | 3 (9%)                            |
| Duration of MGD (years) | 4.4 ± 2.5                           | 5.1 ± 3.1                         |
| History of MGX          | 15 (50%)                            | 20 (59%)                          |
| History of MGP          | 6 (20%)                             | 6 (18%)                           |

M male, F female, MGD meibomian gland dysfunction, MGX meibomian gland expression, MGP meibomian gland probing.
In the present study, IPL therapy was combined for the first time with Activa mask for 3 in-office sessions. This treatment provided significant improvement of all clinically meaningful metrics in patients with MGD. These positive results highlight the potential synergistic role of these two procedures when combined in the same session. However, beyond the strengths we recognize the limitation of the study design that included an historical control group of patients treated with IPL as the only therapy. A prospective randomized controlled study comparing the techniques used alone or in combination should be conducted in order to confirm and validate these findings.

**Conclusions**

In conclusion, the interest and the use of new physical in-office therapies in the setting of MGD are continuously growing. These procedures can be used alone or in combination with other therapies (medical and/or physical) [31]. The present study showed that serial sessions incorporating the application of an eye mask producing heating and vibration immediately followed by IPL therapy are able to improve all ocular surface parameters as well as ocular discomfort symptoms in patients with MGD, while avoiding the need for using other medications (e.g. corticosteroids) apart from tear substitutes.

**Acknowledgments**

None.

**Authors’ contributions**

Luca Vigo: Conceptualization, Data Collection, Manuscript Reviewing and Editing; Marco Pellegrini: Data Curation, Manuscript Reviewing and Editing; Francesco Carones: Supervision, Manuscript Reviewing and Editing; Vincenzo Scorcia: Supervision, Manuscript Reviewing and Editing; Giuseppe Giannacare: Conceptualization, Manuscript Writing. The authors read and approved the final manuscript.

**Funding**

No funding or grant support.
Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available due to their proprietary nature, but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study followed the tenets of the Declaration of Helsinki for research involving human subjects. This study protocol was reviewed and approved by Comitato Etico Regione Calabria – Sezione Area Centro. Written informed consent was obtained from all participants after the nature and possible consequences of the study had been explained to them.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Carones Ophthalmology Center, Milan, Italy. 2 Department of Translational Medicine, University of Ferrara, Ferrara, Italy. 3 Ospedali Privati Forlì “Villa Igea”, Department of Ophthalmology, Forlì, Italy. 4 Istituto Internazionale per la Ricerca e Formazione in Oftalmologia, Forlì, Italy. 5 Department of Ophthalmology, University “Magna Graeca” of Catanzaro, Viale Europa, 88100 Germaneto (Catanzaro), Italy.

Received: 25 March 2022 Accepted: 11 July 2022 Published online: 19 July 2022

References
1. Giannaccare G, Vigo L, Pellegrini M, et al. Ocular surface workup with automated noninvasive measurements for the diagnosis of Meibomian gland dysfunction. Cornea. 2018;37:740–5.
2. Knop E, Knop N, Millar T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52:1938–1978.
3. Nichols KK, Foukis GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922–9.
4. Rabensteinner DF, Amínfar H, Boldin I, et al. The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol. 2018;96:e707-e711.
5. Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65:205–17.
6. Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea. 2019;38:565–73.
7. Greiner JV. A single LipiFlow® thermal pulsation system treatment improves meibomian gland function and reduces dry eye symptoms for 9 months. Curr Eye Res. 2012;37:272–8.
8. Arita R, Fukuoka S. Non-pharmacological treatment options for meibomian gland dysfunction. Clin Exp Ophthalmol. 2020;103:742–55.
9. Vigo L, Pellegrini M, Carones F, et al. Short-term effects of a novel eye mask producing heat and vibration for the treatment of dry eye disease: a pilot study. J Ophthalmol. 2021. https://doi.org/10.1155/2021/1370002.
10. Li D, Lin SB, Cheng B. Intense pulsed light: from the past to the future. Photomed Laser Surg. 2016;34:435–47.
11. Dell SJ. Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol. 2017;11:1167–73.
12. Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017;183:81–90.
13. Giannaccare G, Taroni L, Senni C, et al. Intense pulsed light therapy in the treatment of Meibomian gland dysfunction: current perspectives. Clin Ophthalmol (Auckl). 2019;11:113–26.
14. Toyros R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction: a 5-year retrospective study. Photomed Laser Surg. 2015;33:41–6.
15. Gupta PK, Vora GK, Matossian C, et al. Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol. 2016;51:249–53.
16. Vegunta S, Patel D, Shen JF. Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGE) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea. 2016;35:318–22.
17. Jiang X, Lv H, Song H, et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol. 2016;2016:1910694.
18. Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Ophthalmol. 2018;101:23–33.
19. Arita R, Miozguchi T, Fukuoka S, et al. Multicenter study of intense pulsed light therapy for patients with refractory meibomian gland dysfunction. Cornea. 2018;37:1566–71.
20. Mejía LF, Gil JC, Jaramillo M. Intense pulsed light therapy: a promising complementary treatment for dry eye disease. Arch Soc Esp Oftalmol. 2019;94:331–6.
21. Choi M, Han SJ, Ji YW, et al. Meibum Expressibility improvement as a therapeutic target of intense pulsed light treatment in meibomian gland dysfunction and its association with tear inflammatory cytokines. Sci Rep. 2019;9:1–8.
22. Vigo L, Giannaccare G, Sebastiani S, et al. Intense pulsed light for the treatment of dry eye owing to Meibomian gland dysfunction. J Vis Exp 2019. DOI: https://doi.org/10.3791/57811.
23. Ahmed SA, Taher IME, Ghoneim DF, et al. Effect of intense pulsed light therapy on tear proteins and lipids in meibomian gland dysfunction. J Ophthalmic Vis Res. 2019;14:3–10.
24. Vigo L, Taroni L, Bernabei F, et al. Ocular surface workup in patients with Meibomian gland dysfunction treated with intense regulated pulsed light. Diagnostics (Basel). 2019;9:147.
25. Craig JP, Chen YH, Turnbull PRK. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2015;56:1965–70.
26. Yan X, Hong J, Jin X, et al. The efficacy of intense pulsed light combined with Meibomian gland expression for the treatment of dry eye disease due to Meibomian gland dysfunction: a multicenter. Randomized Controlled Trial Eye Contact Lens. 2021;47:45–53.
27. Valencia-Nieto L, Novo-Diez A, Blanco-Vazquez M, et al. Therapeutic instruments targeting meibomian gland dysfunction. Ophthalmol Ther. 2020;9:797–807.
28. Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction: a multicenter, randomized controlled trial. JAMA Ophthalmol. 2019;137:803–11.
29. Huang X, Qin Q, Wang L, et al. Clinical results of Intraductal Meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive Meibomian gland dysfunction: a randomized controlled trial. BMC Ophthalmol. 2019;19:211.
30. Stonecipher K, Abell TG, Chotiner B, et al. Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. Clin Ophthalmol. 2019;13:993–9.
31. Giannaccare G, Pellegrini M, Caroneva Scalzo G, et al. Low level therapy versus intense pulsed light for the treatment of Meibomian gland dysfunction: preliminary results from a prospective randomized comparative study. Cornea. 2021. https://doi.org/10.1155/2021/1370001.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.